Archer produces graphene inks
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Archer Exploration (ASX:AXE) has provided results from its collaboration with The University of Adelaide.
The company has informed the market that graphene inks were prepared using a combination of established, publically available and proprietary methods – which took advantage of its chemically superior Campoona graphite.
It’s worth noting that remains a speculative play and investors should seek professional financial advice if considering this company for their portfolio.
Two printing techniques were undertaken during the trial, which utilised an inkjet printer and a laser-scribed printer for the preparation of basic electrode patterns (below).
AXE has noted that the electrochemical characteristics of the printed electrodes were obtained, and are adequate for biosensor application use.
The properties of the inks have yet to be thoroughly tested or optimised, and will be the subject of the ongoing collaboration.
The University of Adelaide verified the authenticity of the graphene materials, properties and quality via technical analysis. This analysis included cyclic voltametric experiments that confirmed the capability of the printed electrodes to be used in electrochemical biosensor applications.
In addition, the technical analysis confirmed that graphite sourced from AXE’s Campoona deposit could be used to produce graphene-based inks and printed electrodes in-line with or better than benchmarks set in related research fields.
Both parties will now prioritise securing intellectual property rights to commercially available technology in relation to the inks.
AXE CEO Dr Mohammad Choucair spoke on the announcement, “The work with The University of Adelaide Graphene Hub highlights our continue and successful collaborative efforts in executing our advanced materials and technology strategy, and provides Archer with commercial opportunities to develop high-end graphene products and technologies in the focus area of human health, to underpin further development of our Campoona graphite resource.”
Graphene inks and printed graphene electronic device products form part of the emerging US$2 billion conductive ink technology market.
This market is set to service niche segments of the global biosensor space, which is expected to grow to US$27 billion by 2022.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.